How is tesamorelin with ipamorelin dosed and mixed?

Draw to

unitsmL

0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe

051015202530 01020304050 0102030405060708090100 00.511.522.53 05101520 010203040

    mL
    Syringe scale
    Syringe

    Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.

    Save to Milligram
    How often

    Open in Milligram shows once the calculator has a result.

    Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.

    Open in Milligram is off while the draw is under one unit. Check the dose and its unit.

    Open in Milligram adds Tesamorelin and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.

    The tesamorelin labels give 1.4 mg once daily (EGRIFTA SV) or 1.28 mg once daily (EGRIFTA WR), two products the WR label calls not substitutable, and no label or human trial gives a dose for it with ipamorelin.12

    Every vial at a glance. Pick a cell to draw it on the syringe.

    Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
    Vial1 mL of water2 mL of water3 mL of water
    10 mg10 mg/mL: 1,000 mcg is 10 units, 2,000 mcg is 20 units5 mg/mL: 1,000 mcg is 20 units, 2,000 mcg is 40 units3.333 mg/mL: 1,000 mcg is 30 units, 2,000 mcg is 60 units
    20 mg20 mg/mL: 1,000 mcg is 5 units, 2,000 mcg is 10 units10 mg/mL: 1,000 mcg is 10 units, 2,000 mcg is 20 units6.667 mg/mL: 1,000 mcg is 15 units, 2,000 mcg is 30 units

    Jump to a vial 10 mg 20 mg

    Vial, water and syringe units

    Of the people logging tesamorelin, 65% set up a 10 mg vial, 26% a 20 mg vial and 5% a 5 mg vial.10 The tesamorelin labels give a 2 mg single-dose vial (EGRIFTA SV) and an 11.6 mg single-patient-use vial (EGRIFTA WR).12 The searches for this guide found no label or allowed source giving vial strengths for ipamorelin, or for one vial holding both peptides.

    Of the people logging tesamorelin, 28% set up 10 mg with 2 mL, 26% 10 mg with 1 mL and 16% 20 mg with 2 mL.10 Of the same people, 38% logged a 2 mg dose and 36% a 1 mg dose.10 The syringe mark and calculator below are for a tesamorelin-only vial, set up with the 10 mg with 2 mL mix and the 2 mg dose from these tesamorelin logs, and 8% of people logging tesamorelin logged 2 mg at 40 units; no label or human trial gives a dose for the two peptides together.10

    The calculator is at the top of the page

    What the tesamorelin labels give

    The EGRIFTA SV label gives 1.4 mg once daily, which is 0.35 mL from a 2 mg vial mixed with 0.5 mL of the Sterile Water provided.1 The EGRIFTA WR label gives 1.28 mg once daily, which is 0.16 mL from an 11.6 mg vial mixed with 1.3 mL of Bacteriostatic Water, a solution the label gives as 8 mg per mL, and one mixed vial covers 7 daily doses.2 Both labels give these doses for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.12 The WR label says the two products are not substitutable, and that its 1.28 mg gives exposure similar to the 2 mg dose of the earlier formulation.2 The SV label says the same of its 1.4 mg dose: exposure similar to the 2 mg dose of the earlier 1 mg per vial EGRIFTA formulation.1 The SV label says to inject subcutaneously into the abdomen and to rotate sites.1 No label or leaflet gives water or a volume for ipamorelin or for a blend.

    What the trials gave

    The searches for this guide found no label or human trial of the two peptides together, so each trial below gave one of them. The ipamorelin trials found were all intravenous.

    TrialDose and schedulePeopleLength
    Falutz et al., NEJM, 20073Tesamorelin 2 mg under the skin daily, or placebo412 patients with HIV and abdominal fat (86% men)26 weeks
    Falutz et al., pooled analysis of two phase 3 trials, 20104Tesamorelin 2 mg (n = 543) or placebo (n = 263) under the skin daily; at week 26, tesamorelin 2 mg (n = 246) or placebo (n = 135), and placebo patients switched to tesamorelin (n = 197)806 HIV patients on antiretroviral therapy with excess abdominal fat26 weeks, then 26 more
    Beck et al., 20145Ipamorelin 0.03 mg/kg twice daily by intravenous infusion, or placeboOne hundred seventeen adults enrolled after small or large bowel resection (114 analysed)Day 1 to 7 or discharge
    Helsinn phase 2 dose-finding trial, NCT01280344 (2011 to 2014)6Ipamorelin by intravenous infusion: 0.03 mg/kg twice daily, 0.06 mg/kg twice daily, 0.06 mg/kg three times daily, or saline placebo three times daily320 enrolled patients after small or large bowel resectionOutcomes measured up to 10 days
    Gobburu et al., 19997Ipamorelin by infusion over 15 minutes at 4.21, 14.02, 42.13, 84.27 or 140.45 nmol/kg, in dose escalationEight healthy men at each dose level15-minute infusion

    Storage

    The SV label says to store the unmixed 2 mg vial at 20 to 25 °C in its original box, and not to store, freeze or refrigerate it once mixed.1 The WR label says to store the unmixed 11.6 mg vial at 20 to 25 °C in its original box, and to store the reconstituted vial at 20 to 25 °C and discard unused solution 7 days after mixing; its leaflet says not to freeze or refrigerate it once mixed.2 No label or leaflet gives storage for ipamorelin or for a blend, before or after mixing.

    Frequently asked questions

    What is the difference between tesamorelin and ipamorelin?

    A review describes tesamorelin as a GHRH analogue with an FDA-approved indication in HIV-associated lipodystrophy, and ipamorelin as a synthetic growth hormone secretagogue that acts as a relatively selective agonist of the GHSR-1a receptor.8

    Does ipamorelin have a label?

    A DailyMed search found no ipamorelin label. A 2026 review of injectable peptides in sports medicine says growth hormone axis secretagogues, including ipamorelin and tesamorelin, remain investigational, with uncertain safety profiles, product quality concerns and widespread antidoping restrictions.9

    How the logged figures are counted

    Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.

    References

    1. Theratechnologies (DailyMed). These highlights do not include all the information needed to use EGRIFTA SV safely and effectively. See full prescribing information for EGRIFTA SV. EGRIFTA SV ® (tesamorelin) for injection, for subcutaneous use Initial U.S. Approval: 2010. 2026. dailymed.nlm.nih.gov
    2. Theratechnologies (DailyMed). These highlights do not include all the information needed to use EGRIFTA WR safely and effectively. See full prescribing information for EGRIFTA WR. EGRIFTA WR™ (tesamorelin) for injection, for subcutaneous use Initial U.S. Approval: 2010. 2026. dailymed.nlm.nih.gov
    3. PubMed. Metabolic effects of a growth hormone-releasing factor in patients with HIV. 2007. pubmed.ncbi.nlm.nih.gov
    4. PubMed. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. 2010. pubmed.ncbi.nlm.nih.gov
    5. PubMed. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. 2014. pubmed.ncbi.nlm.nih.gov
    6. ClinicalTrials.gov. NCT01280344: Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function. 2014. clinicaltrials.gov
    7. PubMed. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. 1999. pubmed.ncbi.nlm.nih.gov
    8. Frontiers in Endocrinology. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. 2026. pmc.ncbi.nlm.nih.gov
    9. PubMed. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. 2026. pubmed.ncbi.nlm.nih.gov
    10. Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted